Cargando…

FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses

BACKGROUND: Fibroblast growth factor 15 (FGF15) through its FGF-receptor (FGFR)-4 inhibits hepatic inflammation. The current study aimed at investigating whether FGF15 could inhibit septic inflammation and its compensative regulatory T cell (Treg) responses in a mouse sepsis model of cecal ligation...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xing, Zhu, Zexiang, Xia, Zhenkun, Xu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653038/
https://www.ncbi.nlm.nih.gov/pubmed/36386580
http://dx.doi.org/10.2147/JIR.S387613
_version_ 1784828601682624512
author Li, Xing
Zhu, Zexiang
Xia, Zhenkun
Xu, Bo
author_facet Li, Xing
Zhu, Zexiang
Xia, Zhenkun
Xu, Bo
author_sort Li, Xing
collection PubMed
description BACKGROUND: Fibroblast growth factor 15 (FGF15) through its FGF-receptor (FGFR)-4 inhibits hepatic inflammation. The current study aimed at investigating whether FGF15 could inhibit septic inflammation and its compensative regulatory T cell (Treg) responses in a mouse sepsis model of cecal ligation and puncture (CLP) and in vitro transwell co-culture. METHODS: Following the sham or CLP procedure, male CLP C57BL/6 mice were intravenously injected with vehicle saline or FGF15 beginning at 2 h post the procedure every 12 h for three days. Some mice were euthanized and their serum and liver samples were collected for examination of cytokines and Tregs by enzyme-linked immunosorbent assay (ELISA), Western blot and flow cytometry. The remaining mice were monitored for their survival up to 14 days post procedure. Moreover, the purified hepatic CD4+ T cells were co-cultured in transwell plates with unmanipulated NCTC 1469 cells or the cells that had been transfected with the control or FGFR4-specific siRNA and treated with, or without, Lipopolysaccharides (LPS) for 24 h, followed by treatment with vehicle PBS or FGF15 for 48 h. RESULTS: Compared with the CLP group of mice, treatment with FGF15 significantly prolonged the mean survival days of mice (12 vs 1.17 in the CLP group, P = 0.022), mitigated hepatic inflammation and reduced the frequency of apoptotic cells in the liver of mice. FGF15 treatment decreased the percentages of hepatic Tregs, hepatic IL-2, TGF-β and FOXP3 expression in septic mice, accompanied by decreasing serum IL-1β, TNF-α, IL-6 and IL-10 levels. Similarly, FGF15 treatment also attenuated the LPS-increased frequency of Tregs, FOXP3 and IL-2 expression and IL-1β, TNF-α, IL-6 and IL-10 secretion in vitro after co-culture with NCTC 1469 cells, but not co-cultured FGFR4-silenced NCTC 1649 cells. CONCLUSION: FGF15 treatment through FGFR4 ameliorated hepatic inflammation and its compensative Treg responses, which were associated with protecting from septic death in mice.
format Online
Article
Text
id pubmed-9653038
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-96530382022-11-15 FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses Li, Xing Zhu, Zexiang Xia, Zhenkun Xu, Bo J Inflamm Res Original Research BACKGROUND: Fibroblast growth factor 15 (FGF15) through its FGF-receptor (FGFR)-4 inhibits hepatic inflammation. The current study aimed at investigating whether FGF15 could inhibit septic inflammation and its compensative regulatory T cell (Treg) responses in a mouse sepsis model of cecal ligation and puncture (CLP) and in vitro transwell co-culture. METHODS: Following the sham or CLP procedure, male CLP C57BL/6 mice were intravenously injected with vehicle saline or FGF15 beginning at 2 h post the procedure every 12 h for three days. Some mice were euthanized and their serum and liver samples were collected for examination of cytokines and Tregs by enzyme-linked immunosorbent assay (ELISA), Western blot and flow cytometry. The remaining mice were monitored for their survival up to 14 days post procedure. Moreover, the purified hepatic CD4+ T cells were co-cultured in transwell plates with unmanipulated NCTC 1469 cells or the cells that had been transfected with the control or FGFR4-specific siRNA and treated with, or without, Lipopolysaccharides (LPS) for 24 h, followed by treatment with vehicle PBS or FGF15 for 48 h. RESULTS: Compared with the CLP group of mice, treatment with FGF15 significantly prolonged the mean survival days of mice (12 vs 1.17 in the CLP group, P = 0.022), mitigated hepatic inflammation and reduced the frequency of apoptotic cells in the liver of mice. FGF15 treatment decreased the percentages of hepatic Tregs, hepatic IL-2, TGF-β and FOXP3 expression in septic mice, accompanied by decreasing serum IL-1β, TNF-α, IL-6 and IL-10 levels. Similarly, FGF15 treatment also attenuated the LPS-increased frequency of Tregs, FOXP3 and IL-2 expression and IL-1β, TNF-α, IL-6 and IL-10 secretion in vitro after co-culture with NCTC 1469 cells, but not co-cultured FGFR4-silenced NCTC 1649 cells. CONCLUSION: FGF15 treatment through FGFR4 ameliorated hepatic inflammation and its compensative Treg responses, which were associated with protecting from septic death in mice. Dove 2022-11-08 /pmc/articles/PMC9653038/ /pubmed/36386580 http://dx.doi.org/10.2147/JIR.S387613 Text en © 2022 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Xing
Zhu, Zexiang
Xia, Zhenkun
Xu, Bo
FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses
title FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses
title_full FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses
title_fullStr FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses
title_full_unstemmed FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses
title_short FGF15 Protects Septic Mice by Inhibiting Inflammation and Modulating Treg Responses
title_sort fgf15 protects septic mice by inhibiting inflammation and modulating treg responses
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653038/
https://www.ncbi.nlm.nih.gov/pubmed/36386580
http://dx.doi.org/10.2147/JIR.S387613
work_keys_str_mv AT lixing fgf15protectssepticmicebyinhibitinginflammationandmodulatingtregresponses
AT zhuzexiang fgf15protectssepticmicebyinhibitinginflammationandmodulatingtregresponses
AT xiazhenkun fgf15protectssepticmicebyinhibitinginflammationandmodulatingtregresponses
AT xubo fgf15protectssepticmicebyinhibitinginflammationandmodulatingtregresponses